Recent Updates
Recently added Catalysts

Nitrofurantoin Macrocrystals

Phase 1

Healthy | Small molecule | Other |Viatris Inc.|Last Updated: Apr 24, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment28
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00649506Food Study of Nitrofurantoin Macrocrystals 100 mg Capsules and Macrodantin® 100 mgPHASE1 COMPLETED 28Sep 1, 2003Sep 1, 2003Apr 24, 20241 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Bioequivalence
within 30 days
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER
Treatment Arms
ArmTypeDescription
1EXPERIMENTALNitrofurantoin Macrocrystals 100 mg Capsules
2ACTIVE_COMPARATORMacrodantin® 100 mg Capsules
Interventions
NameTypeDescription
Nitrofurantoin Macrocrystals 100 mg CapsulesDRUG100mg, single dose fed
Macrodantin® 100 mg CapsulesDRUG100mg, single dose fed
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum Beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to of the study and on the evening prior to e...

Countries:United States
Unlock Eligibility Criteria